Using a composite score of four blood biomarkers may be useful for predicting the risk of type 2 diabetes (T2D) in a Chinese population, suggests the nested case-control analysis of the Singapore Chinese Health Study (SCHS).
In postmenopausal women, severe energy restriction led to greater weight, fat, and whole-body lean mass loss than that achieved with moderate energy restriction, according to results of the TEMPO* Diet trial conducted in Sydney, Australia. However, there was a tendency toward greater loss in total hip bone mineral density (BMD) with severe energy restriction.
An association exists between weight gain and a decrease in responsivity of regions connected to taste and reward processing to palatable high-fat and high-fat/high-sugar food tastes, a study has shown. Moreover, avoiding weight gain can increase the sensitivity of taste, which then helps prevent future excessive weight gain.
Use of a closed-loop system, also known as the artificial pancreas, led to better glycaemic control in terms of more time spent in the target glycaemic range than a sensor-augmented insulin pump in patients with type 1 diabetes (T1D), according to the iDCL* study.
There is a high prevalence of metabolic syndrome (MetS) in patients with psoriasis in Singapore, which is nearly threefold higher than the general population, a study has shown. However, no association exists between disease severity and presence of MetS.
An enzyme-linked immunosorbent assay (ELISA) is better at detecting glutamic acid decarboxylase antibodies (GADAb) than the previously utilized radioimmunoassay in childhood-onset type 1 diabetes mellitus (T1DM), a new study has found.
Patients with chronic obstructive pulmonary disease (COPD) who initiate treatment with inhaled corticosteroids (ICS) may have an elevated risk of developing type 2 diabetes mellitus (T2DM), according to a matched cohort study.
Oral form of the GLP-1* analogue semaglutide was superior to the SGLT-2i** empagliflozin in reducing HbA1c in patients with type 2 diabetes (T2D) uncontrolled on metformin, according to the head-to-head PIONEER 2*** trial.
Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.